RELIEF: Remibrutinib in Chronic Spontaneous Urticaria: Early Real World Effectiveness and Satisfaction Survey
This is a United States (US) based, prospective, non-interventional, provider-referral study to evaluate the real-world effectiveness and patient-centered outcomes of remibrutinib in chronic spontaneous urticaria (CSU) patients using validated patient reported outcome (PRO) tools.
‣ Healthcare provider (HCP) participants eligible to refer patients for inclusion in this study must meet all the following criteria:
• Have an active medical license and be board certified/board eligible allergist or dermatologist in the US. Nurse practitioners and physician assistant practicing in allergy and dermatology are eligible.
• Manage CSU patients within their practice.
• Enrolled in the research network or are referred HCPs who agree to participate.
• Have the requisite patient population based on study inclusion/exclusion criteria.
• Patients eligible for inclusion in this study must meet all of the following criteria:
• ≥ 18 years of age.
• Diagnosed with CSU by an HCP.
• Have received a prescription for remibrutinib or dupilumab and are expected to initiate treatment.
• Have access to an electronic device with internet capabilities.
• Able to read and understand English.
⁃ Willing and able to provide consent for study participation.